Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
18.77
-0.78 (-3.99%)
Feb 11, 2026, 11:25 AM EST - Market open
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$236,292
Profits / Employee
-$110,654
Market Cap
2.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | 1,194 | 502 | 72.54% | 1,194 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 1,372 |
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 291 |
| Harmony Biosciences Holdings | 268 |
| Soleno Therapeutics | 152 |
ZLAB News
- 1 day ago - Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 - Business Wire
- 8 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
- 4 weeks ago - Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - Business Wire
- 5 weeks ago - Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
- 2 months ago - Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire